Updated 08:05 GMT, 20 Nov 2026 SPX 7,175.83 -2.02% NDX 26,517.05 -2.21% VIX 28.44 +15.80% GOLD 3,574.90 -3.00% CL 82.63 -0.70% BTC 61,735.58 -0.27%
NAS100 26,517 −2.21% S&P 7,176 −2.02% GOLD $3,575 −3.00% BTC $61,736 −0.27% VIX 28.44 +15.80% latest tape · as of 08:05 UTC
The Screen · Consumer Cyclical · Personal Services

MEDIROM Healthcare Technologies Inc ADR

MRM · NASDAQ · USD · Market cap $7M · 334 employees

MEDIROM Healthcare Technologies Inc., together with its subsidiaries, provides holistic health services in Japan.

FAIL · Does not pass the screen
0.26 USD

Price as of 18 Nov 2026Daily close, not a live quote

Screened 2026-11-18 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price0.26 USD at the 18 Nov 2026 close
  • Our regime readMarkdown, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed18 Nov 2026 (2 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-18).

Current read
Markdown ?
Screened · screened 2026-11-18
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price0.26 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-17Read Markdown0.28-4.7% to today ✓Distribution gives way to Markdown after a 16% slide in 4 weeks
2026-10-17Read Distribution0.33-20.0% to today ✓Markdown gives way to Distribution after a 56% slide in 2 weeks
2026-10-02Read Markdown0.75-64.8% to today ✓Accumulation gives way to Markdown after a 19% slide in 4 weeks
2026-09-05Read Accumulation0.93-71.6% to today Markdown gives way to Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

MEDIROM Healthcare Technologies Inc ADR holds its Markdown at $0.26. Consolidating, no directional conviction, held for 6 days.

As held on the ledger · 2026-11-18
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 6 days
Price at the screen$0.26
Valuation2.03 trailing · N/A forward price to earnings
Values screenFAIL · score 70.0
Beta1.01
The Workings

Five Screens: MRM's Results

FAIL. Debt ratio

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 48.91% Below 33% Fail
Interest-bearing cash 1.07% Below 33% Pass
Receivables 20.83% Below 49% Pass
Revenue purity 0.00% Below 5% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

MEDIROM Healthcare Technologies's business is in a permissible area, but its interest-bearing debt is about 49% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when MRM's ethical verdict changes

Today MRM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

The Business, in Plain Words
The fundamentals · plain-English read
Trailing P/E2.0xvery cheap relative to earnings
EPS, trailing0.37
Revenue growth-6.7%revenue is shrinking
Profit margin0.5%barely profitable
Return on equity53.2%an exceptional return on shareholder capital
FCF yield4,252.35%
Debt to equity7.86heavy leverage: higher risk if revenue softens
Current ratio0.24below 1: short-term bills exceed liquid assets
Beta1.01moves a little more than the market
Short interest, float0.02%
52-week range0.90 - 4.45
MoatNONE
Market cap$7M
Employees334

MRM-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Japan and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-17 Markdown · changed $0.28 -2.1% Entry 10

The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-11-10 Distribution $0.28 -18.4% Entry 9

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 18.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-10-30 Distribution $0.35 +5.2% Entry 8

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-10-17 Distribution · changed $0.33 -56.0% Entry 7

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 56.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-10-02 Markdown · changed $0.75 -19.4% Entry 6

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-09-05 Accumulation · changed $0.93 +0.0% Entry 5

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-08-06 Markdown · changed $0.93 -21.2% Entry 4

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 21.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-18 Markup $1.18 +0.0% Entry 3

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-03 Markup $1.18 +0.0% Entry 2

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markup $1.18 Entry 1

Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in MRM's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $0.36 -27.3% · $727 -27.3%
2 months $0.78 -66.2% · $339 -66.2%
3 months $1.00 -73.7% · $263 -73.7%
6 months $1.27 -79.2% · $208 -79.2%
1 year $2.12 -87.6% · $125 -87.6%
2 years $2.75 -90.4% · $96 -90.4%
3 years $5.00 -94.7% · $53 -94.7%
5 years $7.65 -96.6% · $35 -96.6%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever MRM does next, these words stay.

MEDIROM Healthcare Technologies Inc ADR · MRM · Markdown · $0.26
Recorded 2026-11-18 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.